MAOI Antidepressants: Pharmacology Made Easy & Clinically Relevant
MAOI antidepressants offer benefits in treatment-resistant or difficult-to-treat depression, giving them an advantage. However, they also have real side effects & drug interactions that all clinicians must know. Learn to understand by learning the why.
To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why pharmacology review, Dr. Busti demystifies the monoamine oxidase inhibitors (MAOIs)—an older but still clinically relevant antidepressant class. You’ll learn why MAOIs remain valuable for treatment-resistant depression, how they differ mechanistically from SSRIs/SNRIs/TCAs, and what safe, modern usage looks like. The goal = Pharmacology Made Easy
We cover agents and formulations—including the practical distinction between selegiline oral (Parkinson’s disease) vs selegiline transdermal (MDD)—and walk through irreversible MAO-A/MAO-B enzyme inhibition, pharmacodynamic implications, and the rationale behind washout periods. You’ll also get crisp frameworks for drug–drug and drug–food (tyramine) interactions, hypertensive crisis prevention, and real-world monitoring and counseling (patch placement/rotation, MRI precautions, OTC/herbal pitfalls like decongestants and St. John’s wort).
Chapter Table of Contents
00:00 Introduction to MAOI Antidepressants & Historical Context
01:27 Why MAOIs Caution: Safety Concerns, Side Effects & Drug Interactions
04:54 MAOI Clinical Indications: Depression Subtypes & When MAOIs Are Considered
06:00 MAOI Formulations: Oral Agents vs Selegiline Transdermal Patch
07:46 Mechanism of Action: MAO-A vs MAO-B Inhibition & Neurotransmitter Effects
09:16 Serotonin Modulation & Interaction Risks with Other Antidepressants
14:08 Side Effect Profiles: CNS Effects, Orthostasis, Weight Changes & Sleep Disturbance
28:16 Hypertensive Crisis: Tyramine Reactions & High-Risk Foods to Avoid
30:01 Dietary Restrictions Explained: Tyramine Metabolism & Patient Counseling
#monoamineoxidaseinhibitors #MAOI #pharmacology #PsychiatryPharmacology #medicaleducation
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
